Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C406
http://purl.obolibrary.org/obo/NCIT_C406
|
|---|---|
| Preferred Name | Cyclosporine |
| Definitions |
A natural cyclic polypeptide immunosuppressant isolated from the fungus Beauveria nivea. The exact mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release. (NCI04)
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A natural cyclic polypeptide immunosuppressant isolated from the fungus Beauveria nivea. The exact mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release. (NCI04) |
|---|---|
| prefLabel | Cyclosporine
|
| label | Cyclosporine
|
| CHEBI_ID | CHEBI:4031
|
| PDQ_Closed_Trial_Search_ID | 39201
|
| code | C406
|
| prefixIRI | NCIT:C406
|
| in_subset |
See more
See less
|
| Display_Name | Cyclosporine
|
| Preferred_Name | Cyclosporine
|
| FDA_UNII_Code | 83HN0GTJ6D
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C62H111N11O12
|
| Maps_To | Cyclosporine
|
| CAS_Registry | 59865-13-3
|
| NSC Number | 290193
|
| NCI_Drug_Dictionary_ID | 39201
|
| Legacy Concept Name | Cyclosporine
|
| type | |
| ALT_DEFINITION | A drug used to help reduce the risk of rejection of organ and bone marrow transplants by the body. It is also used in clinical trials to make cancer cells more sensitive to anticancer drugs.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 39201
|
| Accepted_Therapeutic_Use_For | Allogenic transplants; prophylaxis of organ rejection in bone marrow; kidney; liver and heart transplants; psoriasis; rheumatoid arthritis; various diseases that involve autoimmune response
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| UMLS_CUI | C0010592
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |